Abstract
This study evaluated the salivary concentrations of lactoferrin (Lf) in HIV-seropositive and -seronegative subjects correlating these levels with the incidence of periodontal disease, quantity of Candida spp and systemic condition of the HIV-seropositives (viral load and T lymphocytes CD-4+ count and antiretroviral therapy).
Whole saliva samples were obtained from 109 subjects who were divided into four groups according to the extent of their HIV infection and their periodontal condition. The salivary Lf concentrations were determined by a standard enzymelinked immunosorbent assay and the quantification of Candida spp. was obtained from all subjects.
Among the HIV- participants, higher concentrations of Lf were found in individuals with periodontal diseases (p<0.0001). A similar result was found for HIV+ participants (p<0.0001). No correlation was found between the concentration of salivary Lf and the quantification of Candida spp or between the Lf concentration and the systemic condition of the HIV+ subjects.
The existence of periodontal diseases can modulate an early inflammatory process in the oral mucosa by increasing the expression of Lf, where Lf can act as an antibacterial peptide in HIV- and HIV+ patients. These results suggest that Lf is a possible marker for periodontal diseases in immunocompetent and immunocompromised subjects.
Keywords: HIV/AIDS, lactoferrin, periodontal disease, quantification of Candida spp, saliva.
Current HIV Research
Title:Lactoferrin, A Marker for Periodontal Disease
Volume: 11 Issue: 3
Author(s): Alan G. Lourenco, Cristiano Nakao, Alcyone A. Machado, Ana C.F. Motta, Ludmilla Tonani, Regina C. Candido and Marilena C. Komesu
Affiliation:
Keywords: HIV/AIDS, lactoferrin, periodontal disease, quantification of Candida spp, saliva.
Abstract: This study evaluated the salivary concentrations of lactoferrin (Lf) in HIV-seropositive and -seronegative subjects correlating these levels with the incidence of periodontal disease, quantity of Candida spp and systemic condition of the HIV-seropositives (viral load and T lymphocytes CD-4+ count and antiretroviral therapy).
Whole saliva samples were obtained from 109 subjects who were divided into four groups according to the extent of their HIV infection and their periodontal condition. The salivary Lf concentrations were determined by a standard enzymelinked immunosorbent assay and the quantification of Candida spp. was obtained from all subjects.
Among the HIV- participants, higher concentrations of Lf were found in individuals with periodontal diseases (p<0.0001). A similar result was found for HIV+ participants (p<0.0001). No correlation was found between the concentration of salivary Lf and the quantification of Candida spp or between the Lf concentration and the systemic condition of the HIV+ subjects.
The existence of periodontal diseases can modulate an early inflammatory process in the oral mucosa by increasing the expression of Lf, where Lf can act as an antibacterial peptide in HIV- and HIV+ patients. These results suggest that Lf is a possible marker for periodontal diseases in immunocompetent and immunocompromised subjects.
Export Options
About this article
Cite this article as:
Lourenco G. Alan, Nakao Cristiano, Machado A. Alcyone, Motta C.F. Ana, Tonani Ludmilla, Candido C. Regina and Komesu C. Marilena, Lactoferrin, A Marker for Periodontal Disease, Current HIV Research 2013; 11 (3) . https://dx.doi.org/10.2174/1570162X11311030006
DOI https://dx.doi.org/10.2174/1570162X11311030006 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy of Fluoroquinolones Against Pathogenic Oral Bacteria
Mini-Reviews in Medicinal Chemistry Eradicating Bacterial Biofilms with Natural Products and their Inspired Analogues that Operate Through Unique Mechanisms
Current Topics in Medicinal Chemistry Recent Patents Review in Microencapsulation of Pharmaceuticals Using the Emulsion Solvent Removal Methods
Recent Patents on Drug Delivery & Formulation Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Injectable <i>In-Situ</i> Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and <i>In-Vitro</i> Evaluation
Current Drug Delivery Biofilms: Recent Developments on an Old Battle
Recent Patents on Biotechnology Contribution of Nanotechnology to Improved Treatment of Periodontal Disease
Current Pharmaceutical Design Vanadium-Substituted Wells-Dawson Potassium Salt as Catalyst for Liquid phase Oxidation of 1,4-dihydropyridine Derivative
Current Catalysis Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Confectionery-based Dose Forms
Current Drug Delivery The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Current Drug Therapy Suppression of Virulence of Porphyromonas gingivalis by Potent Inhibitors Specific for Gingipains
Current Protein & Peptide Science Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Nanofibers Based Antibacterial Drug Design, Delivery and Applications
Current Pharmaceutical Design IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
Current Pharmaceutical Design